TY  - JOUR
T1  - Review on Diagnosis & Management of Gout in Primary Health Care
A1  - Gehan Hamdalla
A1  - Noor Ali AlGhanem
A1  - Hatem Abdulaziz Mohammed AlGhamdi
A1  - Bashayer Fahad AlHazmi
A1  - Majed Rashed AlHarthi
A1  - Mohammed Nawar AlOtaibi
A1  - Amnah Ali Elagi
A1  - Abobakr Ali AlQarni
A1  - Jumanah Ali AlZahrani
A1  - Abeer Fahad AlMutairi
A1  - Saleh Abdullah Mohammed
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2022
VL  - 13
IS  - 2
DO  - 10.51847/mYC2Up8IhA
SP  - 121
EP  - 124
N2  - With a countrywide incidence of 2.5% in the adult population, gout is the most prevalent inflammatory joint disease affecting men over 40 in the UK. Prevalences are similar in other industrialized nations, including the US and New Zealand. Monosodium Urate (MSU) crystals occur and are deposited in joints, most frequently the first metatarsophalangeal joint (MTP), as a result of the hyperuricemia that causes gout. Most gout patients in the UK are treated exclusively in primary care. To ensure that care is provided in accordance with need, it is critical to assess the socioeconomic status (SES) of a community afflicted by a condition. Being from a lower SES group is linked to more GP visits and worse health, according to numerous studies on social disadvantage and health consequences. Some of these studies have been conducted at the neighborhood and individual levels to determine whether any associations are caused by characteristics specific to the community or the patients.
UR  - https://pharmacophorejournal.com/article/review-on-diagnosis-amp-management-of-gout-in-primary-health-care-dxbg3zpugumoryp
ER  -